Myriad, AbbVie expand research collaboration, 5/16
May 2016—Myriad Genetics announced an expanded companion diagnostics research collaboration with AbbVie to support the development of AbbVie’s investigational PARP inhibitor, veliparib.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Digital pathology scanner, 5/16
May 2016—Leica Biosystems introduced the Aperio Versa, a combination digital pathology research scanner for bright-field, fluorescence, and FISH imaging. High levels of automation and an optional 200-slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.
Next-generation molecular diagnostics prototype, 5/16
May 2016—Abbott demonstrated a prototype of the company’s next-generation molecular diagnostics platform at a recent scientific event hosted for its customers. The new system is currently being designed from the ground up based on extensive input from laboratory customers.
Multiplex Staph blood culture panel cleared, 5/16
May 2016—Great Basin Scientific has received FDA clearance for its Staph ID/R Blood Culture Panel. The panel is a sample-to-result, automated, DNA multiplex assay for simultaneous identification of Staphylococcus aureus and Staphylococcus species directly from positive blood cultures.
Sarstedt acquires division of m-u-t GmbH, 5/16
May 2016—The Sarstedt Group has acquired the laboratory automation business of m-u-t GmbH, headquartered in Wedel, Germany, and its direct customer business worldwide.
Horizon, Centauri form joint venture, 5/16
May 2016—Horizon Discovery Group has formed an immuno-oncology joint venture, Avvinity Therapeutics, with Centauri Therapeutics, a U.K.-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases.
CTC recovery kits, 5/16
May 2016—Fluxion Biosciences has launched two kits for enhanced circulating tumor cell isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system.
Affymetrix receives grant, 5/16
May 2016—With a grant from Innovate UK, Affymetrix will develop a health and economic benefits assessment for replacing surveillance cystoscopies with noninvasive genomic profiling from urinary cell-free DNA using the OncoScan FFPE Assay Kit.
Collaboration to validate Zika virus detection panel, 5/16
May 2016—Luminex is collaborating with the Laboratory of Molecular Evolution and Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil, to validate a multianalyte Zika virus assay developed by Luminex partner GenArraytion.
FDA-cleared RPR test system, 5/16
May 2016—Gold Standard Diagnostics announced FDA 510(k) clearance of its AIX1000 Rapid Plasma Reagin Automated Test System for syphilis testing.